权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Cognitive impairment associated with androgen deprivation therapy for prostate cancer

前列腺癌雄激素剥夺疗法相关的认知障碍

基本信息

批准号：
10287767
负责人：
David A Morilak
金额：
$ 30.42万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-12-01 至 2023-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10287767
关键词：
Address Administrative Supplement Adverse effects Age Age of Onset Age-associated memory impairment Alzheimer&apos s Disease Alzheimer&apos s disease diagnosis Alzheimer&apos s disease related dementia Alzheimer&apos s disease risk Anti-Inflammatory Agents Apolipoprotein E Attention Brain CD44 gene CX3CL1 gene Cell Respiration Cognition Coupled Data Development Diagnosis Down-Regulation Ensure Family Fractalkine Functional disorder Future Gene Expression Genes Grant Hippocampus (Brain)IL6 gene Impaired cognition Impairment Implant Inflammatory JAK2 gene Location Malignant Neoplasms Malignant neoplasm of prostate Measures Medial Mediating Metabolic Microglia Nerve Degeneration Parents Pathology Prefrontal Cortex Prostate Cancer therapy Quality of life Rat Strains Rattus Risk Role Signal Transduction Site Sprague-Dawley Rats Survival Rate Synaptic plasticity TREM2 gene Testing Time Visuospatial aging brain androgen deprivation therapy cancer therapy cognitive function cytokine experimental study improved indexing male men middle age neuroinflammation neuropathology novel novel therapeutic intervention older men prostate cancer cell prostate cancer survivors receptor reconstitution response subcutaneous success tau Proteins tau phosphorylation tau-1 tumor

项目摘要

Androgen deprivation therapy (ADT) is a mainstay treatment for prostate cancer. ADT has dramatically increased survival of men with prostate cancer, with a 5-year post-diagnosis survival rate exceeding 98%. Thus, ensuring a strong quality of life for prostate cancer survivors has become an essential component of successful treatment. While undoubtedly a success story in terms of cancer treatment, ADT is accompanied by adverse effects, including significant cognitive impairment that presents a serious challenge to the quality of life for prostate cancer survivors and their families. Further, cognitive impairment associated with ADT compromises compliance, and increases the risk of a subsequent diagnosis of Alzheimer’s Disease (AD) and related dementia. This last observation is especially important, as prostate cancer typically afflicts older men, with a typical age of onset in the mid-to-late 60’s, a time at which age-related cognitive impairment is often just emerging. The purpose of the parent R01 grant with which this administrative supplement is associated is to address the mechanism by which ADT impairs brain function and cognition, and to test a novel therapeutic intervention aimed at improving cognition after ADT. The purpose of this administrative supplement, submitted in response to NOT-AG-20-034, is to begin testing the interacting detrimental influences of cancer pathophysiology and ADT in producing cognitive impairment specifically in the aging brain, and to identify potential factors that may increase the likelihood of developing Alzheimer’s disease and related dementias, including inflammatory signaling related to neurodegeneration, and indices of Alzheimer’s-related neuropathology in the brains of 12-mo old rats, also an age at which age-related cognitive impairment is just starting to emerge. In aim 1, we will test the detrimental effects of ADT on cognition, inflammatory signaling implicated in neurodegeneration, and indices of Alzheimer’s- related neuropathology in the brains of 12-mo old male Sprague-Dawley rats, the strain we have used in this project to date, and the newly reconstituted Copenhagen rat strain that we will use in future studies to introduce prostate cancer. Measures will include cognitive function on the attentional set-shifting test, mediated in the medial prefrontal cortex (mPFC), and visuospatial cognitive function on the novel object location test, mediated in hippocampus (Hipp); measures of neuroinflammatory signaling and AD-related neuropathology in mPFC and Hipp; and brain oxidative metabolic status, assessed by measuring NAD+ in mPFC and Hipp. In aim 2, we will test the hypothesis that prostate cancer pathophysiology amplifies or primes the detrimental effects of ADT on cognition, inflammatory signaling implicated in neurodegeneration, and Alzheimer’s-related neuropathology. We will test the effects of ADTon the same measures in 12-mo old Copenhagen rats bearing prostate cancer tumors, induced by implanting syngeneic Dunning R-3327-G rat prostate cancer cells subcutaneously in the flank. The results of the experiments proposed in this supplement should provide preliminary data toward the development of a future grant aimed at investigating further the role of prostate cancer and its treatment in AD and dementia.

雄激素剥夺疗法（ADT）是前列腺癌的主要治疗方法。ADT急剧增加